Identification of cellular genes showing differential expression associated with hepatitis B virus infection

Fukuhara, Yasuo; Suda, Takafumi; Tamura, Yasushi; Igarashi, Masato; Waguri, Nobuo; Kawai, Hirokazu; Aoyagi, Yoshinobu

doi:10.4254/wjh.v4.i4.139

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to determine whether the HBx is really responsible for the differential expression of genes in HepG2 and Hep3B cells, we examined the reported alteration of gene expression in HBx knockdown studies. Surprisingly, we found that none of the genes listed in Table 1 has been reported to be either up-or down-regulated in the human cells (Xie et al 2011) or in mouse model (Fukuhara et al 2012) when HBx is knocked down. This finding seems to suggest that the differential expression of genes between HepG2 and Hep3B is not simply dependent on HBx.…”

Section: Underlying Mechanisms Responsible For the Differences Betweementioning

confidence: 66%

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B

Qiu

Xie

et al. 2014

Cytotechnology

View full text Add to dashboard Cite

As cellular models for in vitro liver cancer and toxicity studies, HepG2 and Hep3B are the two most frequently used liver cancer cell lines. Because of their similarities they are often treated as the same in experimental studies. However, there are many differences that have been largely over-sighted or ignored between them. In this review, we summarize the differences between HepG2 and Hep3B cell lines that can be found in the literature based on PubMed search. We particularly focus on the differential gene expression, differential drug responses (chemosensitivity, cell cycle and growth inhibition, and gene induction), signaling pathways associated with these differences, as well as the factors in governing these differences between HepG2 and Hep3B cell lines. Based on our analyses of the available data, we suggest that neither HBx nor p53 may be the crucial factor to determine the differences between HepG2 and Hep3B cell lines although HBx regulates the expression of the majority of genes that are differentially expressed between HepG2 and Hep3B. Instead, the different maturation stages in cancer development of the original specimen between HepG2 and Hep3B may be responsible for the differences between them. This review provides insight into the molecular mechanisms underlying the differences between HepG2 and Hep3B and help investigators especially the beginners in the areas of liver cancer research and drug metabolism to fully understand, and thus better use and interpret the data from these two cell lines in their studies.

show abstract

Section: Underlying Mechanisms Responsible For the Differences Betweementioning

confidence: 66%

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B

Qiu

Xie

et al. 2014

Cytotechnology

View full text Add to dashboard Cite

show abstract

What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Finelli

Tarantino

2013

WJG

168

125

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is recognized as the most common type of chronic liver disease in Western countries. Insulin resistance is a key factor in the pathogenesis of NAFLD, the latter being considered as the hepatic component of insulin resistance or obesity. Adiponectin is the most abundant adipose-specific adipokine. There is evidence that adiponectin decreases hepatic and systematic insulin resistance, and attenuates liver inflammation and fibrosis. Adiponectin generally predicts steatosis grade and the severity of NAFLD; however, to what extent this is a direct effect or related to the presence of more severe insulin resistance or obesity remains to be addressed. Although there is no proven pharmacotherapy for the treatment of NAFLD, recent therapeutic strategies have focused on the indirect upregulation of adiponectin through the administration of various therapeutic agents and/or lifestyle modifications. In this adiponectin-focused review, the pathogenetic role and the potential therapeutic benefits of adiponectin in NAFLD are analyzed systematically.

show abstract

Identification of cellular genes showing differential expression associated with hepatitis B virus infection

Abstract: The signature of cellular gene expression should provide new information regarding the pathophysiological mechanisms of persistent hepatitis and hepatocarcinogenesis that are associated with HBV infection.

Cited by 2 publications

References 34 publications

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B

Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B

What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Contact Info

Product

Resources

About